Biosergen AB Logo

Biosergen AB

Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.

BIOSGN | ST

Overview

Corporate Details

ISIN(s):
SE0016013460 (+2 more)
LEI:
549300YD2OGUE7BMP925
Country:
Sweden
Address:
Fogdevreten 2, 171 65 Solna
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biosergen AB is a clinical-stage biotechnology company dedicated to developing innovative treatments for life-threatening invasive fungal infections. The company's lead candidate, BSG005, is a genetically improved, fungicidal polyene macrolide designed to offer a superior safety and potency profile compared to current antifungal therapies. BSG005 targets a wide spectrum of fungal pathogens and is primarily being developed for immunocompromised patients, such as those undergoing cancer treatment or organ transplantation. Originating from research at the Norwegian University of Science and Technology, the drug has received FDA Orphan Drug Designation. Through clinical trials and strategic collaborations, Biosergen aims to address the significant unmet medical need in treating severe and resistant fungal diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biosergen AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Biosergen AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France BIM
BioPorto Logo
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
Denmark BIOPOR
Bio Solution Co.,Ltd. Logo
Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.
South Korea 086820
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France ALBIO
Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany BIO3
Biotika A.S. Logo
Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.
Slovakia BSL
Bioton S.A. Logo
Develops and manufactures recombinant human insulin for global diabetes care solutions.
Poland BIO
BIOVENTIX PLC Logo
Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.
United Kingdom BVXP
Bioversys N Logo
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
Switzerland BIOV
Biovica International B Logo
Develops blood tests to monitor the efficacy of solid tumor cancer therapies.
Sweden BIOVIC

Talk to a Data Expert

Have a question? We'll get back to you promptly.